No Data
How is the quality and supply of Pharmaceuticals guaranteed? The National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals.
On December 26, 2024, the National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals, inviting representatives from the National Medical Products Administration, selected Pharmaceutical enterprises, and research Institutions to communicate and exchange views on recent societal concerns regarding quality assurance of centrally procured Pharmaceuticals and innovative development in the Industry, and to listen to opinions and suggestions.
SIMCERE PHARMA (02096.HK) spent HKD 8.95 million to repurchase 1.321 million shares on December 27.
Gelonghui, December 27th丨SIMCERE PHARMA (02096.HK) announced that on December 27th, it repurchased 1.321 million shares at a cost of 8.95 million Hong Kong dollars, with a repurchase price of 6.7-6.8547 Hong Kong dollars per share.
SIMCERE PHARMA (02096.HK) spent 2.9636 million Hong Kong dollars to repurchase 0.44 million shares on December 24.
According to the announcement on December 26 by Gelonghui, SIMCERE PHARMA (02096.HK) stated that on December 24, it spent 2.9636 million Hong Kong dollars to buy back 0.44 million shares, with each repurchase price ranging from 6.7 to 6.7755 Hong Kong dollars. 0.69 million A-shares.
Simcere Pharmaceutical Group Renews Key Agreements
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
BOCOM INTL: The medical insurance work conference again mentioned the Class B catalog and support for the development of commercial insurance, focusing on opportunities related to policy easing.
Recently, the pharmaceutical Sector has experienced a significant fluctuation followed by a decline. Considering that the Sector's valuation is still at a historical low, coupled with the upcoming bullish policies related to finance and medical insurance/commercial insurance and improved liquidity, this institution believes there is still room for further recovery.
Simcere Pharmaceutical Group Limited's (HKG:2096) Business And Shares Still Trailing The Market
No Data
